Latest News From Lumira Ventures

Engage Therapeutics Inc. to Present Phase 2b Data from StATES Study at 2019 American Academy of Neurology Annual General Meeting

Jennifer Schram Engage Therapeutics, Portfolio News

SUMMIT, N.J. (PRNewswire) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience a predictable pattern of  epileptic seizures, today announced it will present clinical data from the open label portion of …